Who are Alogliptin and glimepiride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Incretin-based therapy, Saxagliptin + Metformin, Sitagliptin combined with metformin, Sitagliptin (Januvia), Sitagliptin + Metformin, Vildagliptin (LAF237).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alogliptin-and-glimepiride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Alogliptin and glimepiride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alogliptin and glimepiride (Alogliptin and glimepiride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor and sulfonylurea. Area: Diabetes.

phase 2 DPP-4 inhibitor and sulfonylurea DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Alogliptin and glimepiride (Alogliptin and glimepiride) — Takeda. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and glimepiride is a sulfonylurea that stimulates insulin release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Alogliptin and glimepiride TARGET	Alogliptin and glimepiride	Takeda	phase 2	DPP-4 inhibitor and sulfonylurea	DPP-4
Incretin-based therapy	Incretin-based therapy	Nagaoka Red Cross Hospital	marketed	Incretin mimetic or DPP-4 inhibitor	GLP-1 receptor or DPP-4
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Vildagliptin (LAF237)	Vildagliptin (LAF237)	Novartis	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor and sulfonylurea class)

Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alogliptin and glimepiride — Competitive Intelligence Brief. https://druglandscape.com/ci/alogliptin-and-glimepiride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab